EDEM®, the market leader in Discrete Element Method (DEM) technology for bulk material simulation, today announced that the U.S. Food and Drug Administration (FDA) has purchased EDEM simulation software for pharmaceutical development research.
EDEM is the market leading tool for simulation and analysis of bulk solids and granular materials and it is used in numerous industries including mining, heavy equipment and process manufacturing. In the pharmaceutical industry where bulk solids are involved at almost every stage of the manufacturing process, EDEM is a key predictive tool that can be used to model and optimize a range of processes such as mixing, blending and tablet coating. Companies using EDEM simulation as part of their design process are able to reduce the need for physical prototype and long product development cycles, improve product quality and drive process and product innovation.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of the nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
The FDA will be using EDEM to simulate a range of processes and obtain key insights to drive innovation and optimization in pharmaceutical development and manufacturing research.
Richard LaRoche, CEO of EDEM commented:
“We are pleased to see a key institution like the FDA lead the way by harnessing our simulation technology for their pharmaceutical manufacturing and research activities. EDEM software is used by leading pharmaceutical companies around the globe and it enables them to better understand processes and get key insights leading to optimized processes and innovation in product design”.
For more information about the FDA, visit their website.